The launch of a shingles vaccine and delays to copycat versions of a blockbuster helped Glaxosmithkline to achieve strong quarterly results.
Revenue at Britain’s biggest pharmaceuticals company rose by 6 per cent to £8.1 billion and pre-tax profit by 5 per cent to £1.7 billion in the third quarter.
Trading was boosted by sales of Shingrix, the shingles vaccine, in the United States
But shingles is just chicken pox coming back, isn’t it?
Well, obviously enough, not, but then that’s why no one does get their medical treatment from me.